2008; Lynch et al. 2010), although some improvement in comparison to controls was seen in cross‐over trials, suggesting that patients with vitamin E‐deficient and co‐enzyme Q10‐deficient ataxia may receive some benefit (Cooper et al. 2008). In addition, administration of thyrotropin‐releasing hormone (TRH) was reported to ameliorate cerebellar ataxia in rolling Nagoya mice (Shibusawa et al. 2008) and the TRH analogue taltirelin is approved to improve motor performance in ataxic patients in Japan. This evidence concerns the gene AQP1 and cerebellar ataxia.